With a $50 million gift from Richard and Susan Rogel, University of Michigan Health’s Rogel Cancer Center aims to revolutionize how the world detects, treats and ultimately cures pancreatic cancer.
The gift will create the Rogel and Blondy Center for Pancreatic Cancer in honor of Max Rogel and Allen Blondy, Richard and Susan Rogel’s fathers, both of whom died from cancer.
It will provide support for clinical care and translational research, playing to the strengths of the Rogel Cancer Center’s team of 60 doctors and scientists from 10 departments already working in this area.
This is the first major gift announced during the public phase of the Look to Michigan fundraising campaign, which Richard Rogel chairs for Michigan Medicine and co-chairs at the university level. The Rogels, longstanding U-M supporters, gave $150 million to the cancer center in 2018, which led to the center being named in their honor.
The Rogel and Blondy Center for Pancreatic Cancer will provide resources around a specific disease to achieve transformative impact that cannot be supported by typical grant funding. In this case: doubling the survival rate for pancreatic cancer in the next 10 years.
more information
“My hope is in 10 years they’ll surpass the goal of doubling the survival rate and that Michigan will be the place everyone wants to go for pancreas cancer care. I think we can make a horrible disease a lot more tenable and maybe even cure it,” said Richard Rogel, who recalled his father’s painful death at age 73 from pancreatic cancer. Allen Blondy died from melanoma.
Pancreatic cancer remains one of the deadliest of the major cancers, with a five-year survival rate of only 13%.
“Our team of dedicated researchers and providers is already having a major impact for pancreatic cancer patients and the field. With this generous and visionary gift from Rich and Susan Rogel, we will fuel new initiatives and innovations and strengthen our foundation of excellence in care, discovery and training,” said Eric R. Fearon, director of the Rogel Cancer Center, Emanuel N. Maisel Professor of Oncology, and professor of internal medicine, of pathology and of human genetics.
Pancreatic cancer is complex and stealthy, often escaping notice until it’s advanced and has spread in the body. Rogel researchers have been at the forefront of mapping the tumor microenvironment and understanding how to target tumor metabolism for potential therapies. Their work has contributed to notable improvement in the survival rate from single digits only five years ago.
“Philanthropy has been a driving force behind our major advancements in pancreatic cancer. Our work will be a community success story. The faster we grow our program, the faster we can advance understanding of pancreas cancer and new approaches to save lives,” said Marschall Runge, CEO of Michigan Medicine, dean of the Medical School and executive vice president for medical affairs.
“We are profoundly grateful to Rich and Susan Rogel for their extraordinary and farsighted gift, as well as their sustained and great-hearted support of the university and their leadership in our Look to Michigan campaign,” said President Santa J. Ono. “Their gift will be transformative for Michigan Medicine, opening new discoveries, redefining treatment and even saving and extending lives.”
The new Rogel and Blondy Center will be led by Marina Pasca di Magliano, Maud T. Lane Professor of Surgical Immunology, and professor of surgery and of cell and developmental biology; Costas Lyssiotis, Maisel Research Professor of Oncology, and professor of molecular and integrative physiology and of internal medicine; and Timothy Frankel, Maud T. Lane Professor of Surgical Oncology, and associate professor of surgery.
The gift includes support for four strategic pillars. They are:
- Enhancing and expanding access to world-class patient care.
- Innovating and advancing discovery and translational research.
- Accelerating new treatment options through clinical research and clinical trials.
- Investing in infrastructure, including a biobank and leading-edge research technologies.
“This is unlike anything we’ve ever done before. It’s not how scientists normally think. Instead of getting grants to go from A1 to A2 to A3, they can now think long-term about going all the way from A to Z,” Richard Rogel said.
He described a friend whose brother is being treated for pancreatic cancer and the challenges they’re facing. “If we could take that suffering out of the equation, it would be the greatest thing I ever did,” he said.
This gift brings the Rogels’ total commitment to the Rogel Cancer Center to more than $200 million. They have supported at least 18 different areas across U-M with total giving of nearly $250 million, placing them among the largest individual donors in university history.
Richard Rogel chairs a national advisory board for the Rogel Cancer Center and is a member of the Michigan Medicine Advisory Group and Frankel Cardiovascular Center National Advisory Board, among many others.
Susan Rogel has served on committees benefiting U-M Health’s C.S. Mott Children’s Hospital and Von Voigtlander Women’s Hospital, among many additional efforts.
Richard Rogel is president of the investing firm Tomay Inc., and is the founder and former chairman and CEO of the Preferred Provider Organization of Michigan, which was the first PPO in the country.
Gordon Krainen
It is heart warming knowing that there are such generous and caring people in our community as the Rogels. Truly a wonderful and important gift they are giving.
Lisa Dodge
As a pancreatic cancer survivor, this gift is more than monetary and gives me hope for a better tomorrow. Go Blue, and THANK YOU!